As China's biopharmaceutical industry transitions from a "R&D frenzy" to a more mature stage focused on "commercialization efficiency," the once-neglected manufacturing process is becoming a new arena for competition. Downstream purification processes, crucial for determining the final purity, safety, and production cost of drugs, are undergoing a profound technological revolution. International giants are entering the market with innovative solutions, while domestic research and industrial forces are seeking breakthroughs in core materials and equipment, jointly propelling the leap forward in China's biopharmaceutical manufacturing capabilities.
For a long time, the downstream processing of biopharmaceuticals has relied on traditional "batch processing," which is cumbersome, inefficient, and costly. Each post-production sample testing step leads to production interruptions, resulting in low equipment utilization. The cycle from cell culture to the final drug often takes 30 to 45 days. Meanwhile, Chinese innovative pharmaceutical companies face multiple pressures, including price reductions through medical insurance negotiations and intensified competition in overseas markets, making the need for cost reduction, efficiency improvement, and quality enhancement in the production process unprecedentedly urgent.
Against this backdrop, "continuous biological treatment" and "process enhancement" have become key to breaking the deadlock. Taking Sartorius, a leading supplier in the industry, as an example, its "process enhancement" solution aims to integrate multiple downstream process operation units (such as chromatography, ultrafiltration, and virus removal) in single or multi-step steps, and connect them with upstream continuous perfusion culture through an automated system to form an end-to-end continuous production platform. This model is expected to increase production efficiency by more than ten times and shorten process development time by two months.
Encouragingly, Chinese research institutions and enterprises are making substantial breakthroughs in this "hard technology" field. Research by Academician Ma Guanghui's team from the Chinese Academy of Sciences indicates that domestically produced separation media are moving towards... "Design on demand" It is developing in that direction. For example:
Uniform particle size medium It can achieve high-resolution purification and significantly improve the purity of the target product.
Ultra-large porosity media Its internal structure contains diffusion pores and through pores, which increases the mass transfer efficiency of biological macromolecules by tens of times, making it particularly suitable for purifying complex and easily inactivated ultra-large molecules (such as viral vectors and virus-like particle vaccines).
Surface property controllable media and hybrid mode media By precisely controlling the ligand density, introducing spacer arms, or combining multiple separation mechanisms, the purification challenges of complex biopharmaceuticals such as bispecific antibodies can be effectively addressed.
These innovations are expected to gradually change the situation where high-end separation media are monopolized by foreign countries, laying the foundation for the localization of downstream processes and cost control.
Faced with technological innovation, Chinese pharmaceutical companies have not been quick to adopt it. Ren Xueyun, Head of Technology Application at Sartorius China, observed that many local companies still have concerns about being among the first to adopt innovative processes. Therefore, the role of upstream solution providers is shifting from simply selling products to becoming partners in "growing together" with their customers.
This means that suppliers need a deeper understanding of their clients' needs throughout the entire lifecycle, from R&D and clinical trials to commercialization approval, and even their capital situation and overseas strategies, in order to provide more forward-looking and customized process solutions. This deeply integrated cooperation model is helping Chinese biopharmaceutical companies build internationally competitive production systems more quickly, paving the way for participation in global competition.
Outlook The competition in downstream processes is essentially the ultimate contest between the industrialization capabilities and costs of biopharmaceuticals. In this "second half" of the competition, the localization of internationally advanced technologies and the independent innovation of domestically developed core technologies are happening simultaneously. The convergence and integration of these two will ultimately determine the progress and quality of China's transformation from a "major biopharmaceutical country" to a "leading biopharmaceutical country."
